[HTML][HTML] Selective small molecule inhibitors of p110α and δ isoforms of phosphoinosityl-3-kinase are cytotoxic to human acute myeloid leukemia progenitors
Y Xing, B Gerhard, DE Hogge - Experimental Hematology, 2012 - Elsevier
The phosphoinosityl-3-kinase (PI3K) pathway is frequently constitutively active in blast cells
from acute myeloid leukemia (AML) patients. RNA and protein from all four catalytic isoforms
of PI3K (p110α, β, γ, and δ) were expressed in 38 AML samples, which also showed
expression of phosphorylated Akt Ser473, indicating PI3K activation. Initial treatment of 12
AML samples with inhibitors targeting each of the four isoforms demonstrated that p110α
and δ inhibition are more effective in killing AML blast colony-forming cells (CFC) than …
from acute myeloid leukemia (AML) patients. RNA and protein from all four catalytic isoforms
of PI3K (p110α, β, γ, and δ) were expressed in 38 AML samples, which also showed
expression of phosphorylated Akt Ser473, indicating PI3K activation. Initial treatment of 12
AML samples with inhibitors targeting each of the four isoforms demonstrated that p110α
and δ inhibition are more effective in killing AML blast colony-forming cells (CFC) than …